Partnering with Microchips
We believe the versatility and unique functional aspects of our proprietary platform lend itself to enhance the clinical utility and commercial value of a wide range of established and novel therapeutics.
Our business strategy consists of advancing the development of our own microchip-based applications, while seeking strategic partners to augment our commercialization efforts and collaborate on the development of innovative therapies utilizing our breakthrough drug delivery platform.
To explore potential partnership opportunities, please contact firstname.lastname@example.org.
In June 2015 Microchips Biotech and Teva Pharmaceuticals entered into a partnership under which the companies will explore innovative ways to apply Microchips’ implantable drug delivery device to Teva’s portfolio of products with the goal of enhancing clinical outcomes for patients on chronic drug therapies. The partnership has an initial focus on one selected disease area, but will provide Teva with the option to later expand the program into several additional therapeutic areas and sensing applications that are proprietary to Teva. As programs advance, Microchips Biotech will receive development and commercial milestone payments and royalties on future product sales. Microchips will also receive funding to develop products for any future additional indication Teva may develop, and Teva will be responsible for Phase ll and Phase lll clinical development and regulatory filings. See Press Release
In 2012, we received grants from the Bill & Melinda Gates Foundation to develop a microchip-based contraceptive implant that provides up to 16 years of reversible birth control for women in developing countries who have limited access to routine medical care and modern contraceptive options. The program is still ongoing.